medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2013, Number 2

<< Back Next >>

Biotecnol Apl 2013; 30 (2)

Highlights from Barcelona 2012 International Liver Congress and EASL meeting

Aguilar JC

Language: English
References: 20
Page: 145-148
PDF size: 151.87 Kb.


ABSTRACT

The International Liver Congress 2012 took place at the Centre de Convencions Internacional de Barcelona (CCIB), Spain, on April 18-22. This venue was the 47th annual meeting of the European Association for the Study of the Liver (EASL). The most important novelties of these two events are summarized in the present report.


REFERENCES

  1. Lawitz E, Gane E, Stedman C, Lalezari JP, Hassanein T, Kowdley KV, et al. 7 PSI- 7977 PROTON and ELECTRON: 100 % concordance of SVR4 with SVR24 in HCV GT1, GT2 & GT3. J Hepatol. 2012;56 (Suppl 2):S4.

  2. Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes RG, et al. ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3. J Hepatol. 2012;56 (Suppl 2):S438-9.

  3. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse A, Muellhaupt B, et al. SVR4 and SVR12 with an interferonfree regimen of BI201335 and BI207127, +/- Ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2. J Hepatol. 2012;56(Suppl 2):S45.

  4. Pawlotsky JM, Sarin SK, Foster G, Peng CY, Rasenack J, Flisiak R, et al. Alisporivir plus Ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 OR GT3 patients: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY. J Hepatol. 2012; 56(Suppl 2):S553.

  5. Alberti A, Chuang WL, Flisiak R, Mazzella G, Horban A, Goeser T, et al. ALISPORIVIR (ALV) plus PEG-Interferon/ Ribavirin (PR) IN HCV G1 treatment-experienced patients achieves primary endpoint with superior effi cacy at treatment week 12 compared to retreatment with PR. J Hepatol. 2012;56(Suppl 2):S553-4.

  6. Sulkowski M, Gardiner D, Lawitz E, Hinestrosa F, Nelson D, Thuluvath P, et al. Potent viral suppression with all-oral combination of DACLATASVIR (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/- Ribavirin, in treatment-naive patients with chronic HCV GT1, 2, OR 3. J Hepatol. 2012;56(Suppl 2):S560.

  7. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.

  8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13):975-82.

  9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.

  10. Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, et al. Peginterferon Lambda- 1A (LAMBDA) compared to peginterferon Alfa-2A (ALFA) In treatment-naive patients with HCV genotypes (G) 2 OR 3: fi rst SVR24 results from EMERGE phase IIB. J Hepatol. 2012;56(Suppl 2):S5-S6.

  11. Lawitz E, Poordad F, Kowdley KV, Jensen D, Cohen DE, Siggelkow S, et al. A 12-week interferon-free regimen of ABT-450/R, ABT- 072, and Ribavirin was well tolerated and achieved sustained virologic response in 91 % treatment-naive HCV IL28B-CC genotype-1- infected subjects. J Hepatol. 2012;56(Suppl 2): S7-S7.

  12. Suzuki F, Ikeda K, Toyota J, Karino Y, Ohmura T, Chayama K, et al. Dual oral therapy with the NS5A inhibitor Daclatasvir (BMS-790052) and NS3 protease inhibitor Asunaprevir (BMS-650032) in HCV genotype 1B-INFected null responders or ineligible/intolerant to peginterferon/Ribavirin. J Hepatol. 2012;56(Suppl 2):S7-S8.

  13. Jacobson I, Lawitz E, Lalezari J, Crespo I, Davis M, Hassanein T, et al. PSI-7977 400 MG QD safety and tolerability in the fi rst 450 patients treated for 12 weeks. J Hepatol. 2012; 56(Suppl 2):S441-S41.

  14. Gane EJ, Stedman CA, Hyland RH, et al. PSI-7977: ELECTRON. Interferon is not required for sustained virologic response in treatment-naive patients with HCV GT2 or GT3. Program and abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases; November 5-8, 2011; San Francisco, California. Abstract 34.

  15. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis M, DeMicco M, et al. ATOMIC: 97 % RVR for PSI-7977+PEG/RBV x 12 week regimen in HCV GT1: an end to response-guided therapy? J Hepatol. 2012;56(Suppl 2):S1.

  16. Poordad F, Lawitz E, Kowdley KV, Everson GT, Freilich B, Cohen D, et al. 12-week interferon- free regimen of ABT-450/R +ABT-333- +Ribavirin achieved SVR12 in more than 90 % of treatment-naive HCV genotype-1-infected subjects and 47 % of previous non-responders. J Hepatol. 2012;56(Suppl 2):S549-50.

  17. Le Roy T, Llopis M, Bruneau A, Rabot S, Bevilacqua C, Martin P, et al. Gut microbiota transplantation demonstrates its causal role in the development of type 2 diabetes and fatty liver. J Hepatol. 2012;56(Suppl 2):s23.

  18. Khoruts A, Sadowsky MJ. Therapeutic transplantation of the distal gut microbiota. Mucosal Immunol. 2011;4(1):4-7.

  19. Fagiuoli S, Scalone L, Ciampichini R, Fusco F, Gaeta L, Del Prete A, et al. Societal burden in patients with chronic hepatic diseases: the COME study results. J Hepatol. 2012;56(Suppl 2): s11-2.

  20. Moreau R, Gines P, Jalan R, Pavesi M, Durand F, Angeli P, et al. Diagnosis, prevalence, and prognosis of acute-on-chronic liver failure (ACLF): results of the EASL-chronic liver failure (CLIF) consortium canonic study. J Hepatol. 2012;56(Suppl 2):S552-S53.




2020     |     www.medigraphic.com